^
    1d
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin)
    1d
    ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P1/2, N=41, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1/2 trial
    |
    Meiyouheng (becotatug vedotin) • Qibeian (iparomlimab/tuvonralimab)
    2d
    BL-B01D1-310: A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) (clinicaltrials.gov)
    P3, N=384, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    paclitaxel • topotecan • izalontamab brengitecan (BL-B01D1)
    2d
    A Study of HDM2024 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    5d
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin)
    7d
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 (clinicaltrials.gov)
    P2, N=93, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • Meiyouheng (becotatug vedotin)
    8d
    A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Terminated, Genmab | Trial completion date: Jun 2028 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: May 2028 --> Mar 2026; Genmab has decided to terminate the GEN1286 program due to an unfavorable benefit-risk profile not supporting further development.
    Trial completion date • Trial termination • Trial primary completion date
    9d
    BL-B01D1-302: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) (clinicaltrials.gov)
    P3, N=698, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type
    |
    docetaxel • izalontamab brengitecan (BL-B01D1)
    9d
    Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=430, Recruiting, Ming-Yuan Chen
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    cisplatin • Meiyouheng (becotatug vedotin)
    9d
    BL-B01D1-304: A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) (clinicaltrials.gov)
    P3, N=722, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    topotecan • izalontamab brengitecan (BL-B01D1)
    9d
    BL-B01D1-209: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=40 --> 27
    Enrollment closed • Enrollment change
    |
    izalontamab brengitecan (BL-B01D1)
    9d
    MRG003-SACC: A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Eye & ENT Hospital of Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    epirubicin • Meiyouheng (becotatug vedotin)